Globus Medical cuts 2026 revenue outlook after mixed third-quarter results
+2 new sources since this summary was written
On November 5, 2026, Globus Medical reported third-quarter worldwide net sales of $763.7 million, down 0.7% year over year on a reported basis and down 0.5% on a constant currency basis. GAAP net income was $141.2 million, with GAAP diluted EPS of $1.04, while non-GAAP diluted EPS was $1.23. The company lowered full-year 2026 revenue guidance to $3.09B but reiterated non-GAAP EPS guidance of $4.95-$5.05.
Why it matters
The lower revenue outlook reduces the company’s expected 2026 sales, while the reiterated non-GAAP EPS range leaves its earnings outlook unchanged on that basis. Investors must distinguish the reported revenue decline from the constant currency decline and GAAP EPS from non-GAAP EPS.
Key facts
- 1Third-quarter worldwide net sales were $763.7 million, down 0.7% year over year on a reported basis and down 0.5% on a constant currency basis. stocktitan.net
- 2Base business sales excluding Nevro were $690.0 million, up 3.0% on a reported basis. stocktitan.net
- 3Third-quarter GAAP net income was $141.2 million, and GAAP diluted EPS was $1.04, up 18.2%. stocktitan.net
- 4Third-quarter non-GAAP diluted EPS was $1.23, up 4.4%. stocktitan.net
- 5Globus Medical lowered full-year 2026 revenue guidance to $3.09B and reiterated non-GAAP EPS guidance of $4.95-$5.05. seekingalpha.com
Open questions
- One earnings snapshot describes the per-share result as beating an estimate while citing a higher estimate, and it does not establish the estimate's accounting basis.
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.